Pac Roots Cannabis Corp.

Management's Discussion and Analysis

For the Six Months ended May 31, 2021 and 2020

(Expressed in Canadian Dollars)

Introduction

This Management Discussion and Analysis of the financial condition as of July 28, 2021 provides an analysis of Pac Roots Cannabis Corp. (the "Company")'s financial results and progress for the six months ended May 31, 2021. This MD&A should be read in conjunction with the Company's unaudited condensed interim consolidated financial statements for the period ended May 31, 2021 which were prepared in accordance with accounting policies consistent with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and Interpretations of the IFRS Interpretations Committee ("IFRIC"). All amounts are expressed in Canadian dollars.

Certain statements and information related to the Company's business contained in this Management Discussion and Analysis are of a forward-looking nature. They are based on opinions, assumptions or estimates made by the Company's management or on opinions, assumptions or estimates made available to or provided to and accepted by the Company's management. Such statements and information are reflecting management's current views and expectations of future events or results and are subject to a variety of risks and uncertainties that are beyond management control. Readers are cautioned that these risks and uncertainties could cause actual events or results to significantly differ from those expressed, expected or implied and should therefore not rely on any forward-looking statements.

This MD&A is prepared as at July 28, 2021. All dollar figures stated herein are expressed in Canadian dollars unless otherwise indicated.

Overview

Pac Roots Cannabis Corp. (formerly Mountain Lake Minerals Inc., "MLK"), (the "Company" or "Pac Roots") was incorporated on May 16, 2012 in British Columbia under the Business Corporations Act. The address of the Company's corporate office and its principal place of business is 1055 Hastings Street, Unit 300, Vancouver, British Columbia, Canada.

The Company is in the process of applying for a license to produce cannabis. Operations have not commenced as of the date of the condensed interim consolidated financial statements.

On January 12, 2021, the Company granted 3,450,000 stock options to directors, management and consultants to acquire common shares at a price of \$0.15 per share for a period of three years, ending on January 12, 2024. The fair value of the stock options granted was \$509,949. The fair value was calculated using the Black-Scholes model with the following assumptions: share price at grant date - \$0.19; exercise price - \$0.15; expected life - 3 years; expected volatility - 130.00%; annual rate of dividends - 0%; risk-free rate - 0.23%. Expected volatility was determined based on comparable companies in the same industry.

On January 28, 2021, the Company issued 2,500,000 common shares pursuant to the Phenome Agreement.

On February 22, 2021, the Company closed a share purchase agreement with the shareholders of Lords of Grasstown Holdings Ltd. ("Grasstown") pursuant to which the Company will acquire all the issued and outstanding shares of Grasstown. The total purchase price is comprised of a cash payment of \$50,000 paid on March 22, 2021, and issuance of 6,000,000 common shares issued on February 22, 2021.

On February 23, 2021, the Company granted 400,000 stock options to consultants to acquire common shares at a price of \$0.235 per share for a period of three years, ending on February 23, 2024. The fair value of the stock options granted was \$69,651. The fair value was calculated using the Black-Scholes model with the following assumptions: share price at grant date - \$0.235; exercise price - \$0.235; expected life - 3 years; expected volatility - 130.00%; annual rate of dividends - 0%; risk-free rate - 0.31%. Expected volatility was determined based on comparable companies in the same industry.

On February 24, 2021, the Company closed a non-brokered private placement of 7,448,255 units at a \$0.18 per unit for gross proceeds of \$1,340,686. Each Unit consists of one common share and one share purchase warrant. Each warrant entitles the holder to acquire common shares at a price of \$0.30 per share until February 23, 2024. Aggregate finder's fees of \$75,295 in cash and 408,303 finders' warrants were paid to finders. Each finders' warrant had the same rights as those issued as part of the private placement.

Overview (Continued)

On March 1, 2021, the Company repaid the \$40,000 loan to Phenome One Corp.

Corporate Updates

On December 17, 2020, the Company announced its first successful 100-acre Pilot outdoor Hemp CBD harvest. The Company's joint venture operations team is expecting a 200% to 300% increase in yield for 2021.

On January 6, 2021, the Company announced it has obtained eligibility with the Depository Trust Company "DTC" for its common shares listed on the OTCQB. The DTC is a stock depository that facilitates and simplifies electronic trading of securities in the United States. The Company's common shares, listed on the OTCQB under the symbol PACRF, are not eligible for electronic clearing and settlement through DTC's automated processes. This electronic method speeds up the process for certain investors and provides additional liquidity for existing investors.

On March 19, 2021, the Company has commenced trading in Europe on the Frankfurt Stock Exchange under the symbol "4XM".

Overall Performance

During the period ended May 31, 2021, the Company was still in the process of obtaining a license to produce cannabis. Therefore, minimal operating expenditures were incurred. The Company completed a share purchase agreement for Lords of Grasstown Holdings Ltd. during the period.

Asset Acquisition

1065703 B.C. Ltd.

On April 20, 2018 1157630 BC Ltd. entered into a share purchase agreement (the "Agreement") with 1065703 B.C. Ltd. ("1065703") to acquire 100% of all the issued and outstanding shares of Go Green B.C. Medicinal Marijuana Ltd. ("Go Green") from 1065703 in exchange for \$2,000,000 paid in cash and the issuance of common shares. The consideration is detailed as follows:

- \$275,000 in cash (paid);
- \$225,000 in cash three months following the closing date (paid);
- \$500,000 in cash on or before the earlier of November 15, 2018 or the issuance of a cultivation license by Health Canada (paid); and
- \$1,000,000 in common shares on the earlier of December 15, 2018 or such time as that the Company completes a going public transaction (the "Delivery Date"). The number of common shares issued will be based on the Company's stock price on the Delivery Date.

The details of the purchase have been accounted for as follows during the period ended August 31, 2018:

| Cash paid | \$ 500,000 |
|---|-----------------|
| Cash paid net of accreted interest to November 15, 2018 | 420,000 |
| Fair Value of common shares issued | 1,000,000 |
| Total consideration | \$ 1,920,000 |
| | |
| Intangible asset acquired | \$ 1,920,000 |

The Company has accounted for the purchase as an asset acquisition as it did not meet the criteria under IFRS 3 "Business Combinations" to be classified as a business acquisition. Of the consideration exchanged, \$500,000 was paid during the period ended August 31, 2018 and the remaining balance of \$1,500,000 was set up as a current liability. The Company discounted the liability at a rate of approximately 20% in order to provide for its current present value. The liability will be accreted based on the payment terms noted above. During the year ended August 31, 2019, the Company recorded an accretion expense of \$80,000 and made cash payment of \$500,000.

Asset Acquisition (Continued)

1065703 B.C. Ltd. (Continued)

The intangible asset consisted of in-process licensing application relating to the Go Green's license application to produce cannabis in Canada ("Intangible Asset"). In accordance with the Company's accounting policy, the Intangible Asset is subject to an annual impairment test and as a result the full value of the intangible asset purchased of \$1,920,000 was impaired and charged to the consolidated statement of loss for the period ended August 31, 2018. As of the date of approval of these condensed interim consolidated financial statements, the approval of the processing and cultivation license has not been granted.

During the year ended August 31, 2019, 1157630 and 1065703 amended the terms of the Agreement, whereby 1157630 agreed to increase the share consideration to \$1,015,000, payable on the earlier of November 30, 2019 or such time as the Company completes a going public transaction (issued 3,383,333 shares). Pursuant to the amended Agreement, the market value of the common shares was determined to be \$0.30 per common share. The additional \$15,000 was impaired and charged to the consolidated statement of loss for the year ended August 31, 2019.

The balance payable as at May 31, 2021 and November 30, 2020 is \$Nil.

Phenome One Corp.

On April 8, 2019, MLK entered into a license agreement with Phenome One Corp. ("Phenome") in order to obtain a license (the "Phenome License") from Phenome in respect of a genetic cannabis library of certain cultivars, and technical and materials owned by Phenome in order to allow the Company to propagate, cultivate, harvest, process, breed and develop, manufacture, produce and use such licensed property (the "Phenome Agreement") subject to the following terms:

- 2,500,000 common shares on the date on which the Issuer receives the approval of the CSE for the Fundamental Change Transactions (the "approval date") (Issued);
- 2,500,000 common shares on the date on which is three months following the approval date (Issued);
- 2,500,000 common shares on the date on which is six months following the approval date (Issued);
- 2,500,000 common shares on the date on which is nine months following the approval date (Issued);
- \$50,000 in cash on the date which is 18 months following the approval date;
- \$100,000 in cash on the date which is 24 months following the approval date; and
- \$100,000 in cash on the date which is 30 months following the approval date.

Phenome is a company related to Pac Roots by a common officer.

In addition, Pac Roots will make non-refundable, non-creditable royalty payments to Phenome equal to 5% of gross sales of products, payable within 60 days of each calendar quarter. The Phenome License Agreement will continue for as long as the Pac Roots has payment obligations, including the royalty payments, to Phenome, unless earlier terminated as a result of a breach of the agreement or other circumstances, including where gross sales of products in any two consecutive calendar quarters, after 2019, are less than \$1,000,000. Pac Roots has been granted a right of first refusal to license the rights to any of the licensed cultivars, technology or materials (the "licensed material"), subject to certain exceptions as set forth in the Phenome License Agreement. If Phenome receives a bona fide offer from an independent third party dealing with it at arm's length to acquire such licensed material, it must first offer the licensed material to Pac Roots on terms no less favorable than those offered to it. Pac Roots will have a period of 30 days to accept such offer, failing which Phenome will be entitled to sell the licensed material on the terms specified for a period of 60 days.

Pursuant to terms of the Phenome license, the Company recorded intangible assets of \$2,781,899 representing the discounted fair value of the common share at \$0.30 per share and the cash payable to reflect the time value of money. During the period ended November 30, 2020, the Company issued 7,500,000 common shares with a fair value of \$2,034,666 as a result of the Phenome Agreement and has a remaining commitment to issue 2,500,000 common shares with a discounted value of \$576,360. The Company discounted the cash consideration using a discount rate of 20% to reflect the time value of money related to future cash outlays and discounted the share issuances using the average strike put-option model which resulted in a present value of \$2,781,899 on acquisition date. During the period ended November 30, 2020, the Company recognized accretion expense of \$19,176. As at November 30, 2020, the Company had a consideration payable to Phenome of \$190,049.

Asset Acquisition (Continued)

Phenome One Corp. (Continued)

During the period ended May 31, 2021, the Company recognized accretion expense of \$18,139. As at May 31, 2021, the Company has a consideration payable to Phenome of \$208,189.

During the period ended November 30, 2020, the Company recorded impairment on the intangible assets of \$2,781,899 as the recoverable amount could not be determined reliably. As at May 31, 2021 and November 30, 2020, the balance of intangible assets is \$Nil for the assets acquired from Phenome.

1088070 BC. Ltd.

On September 18, 2020, the Company closed the share purchase agreement (the "1088 Agreement") with 1088070 BC Ltd. ("1088"), to acquire the nine parcels of land comprised of 250 acres of land suitable for cultivation in the Fraser Valley Region of British Columbia owned and controlled by 1088.

The Company will pay an aggregate of \$1.5 million in cash and issue an aggregate of 3 million common shares to the 1088 Shareholders, pro rata in accordance with their holdings as follows (the "Consideration"):

- a) 375,000 shares to be issued on or before the date which is 30 days from the date of Closing (the "1088 Closing Date") (Issued on October 5, 2020);
- b) \$200,000 within three months of the Closing Date (paid*);
- c) \$300,000 in cash and 562,500 common shares within 12 months of the 1088 Closing Date;
- d) \$400,000 in cash and 937,500 common shares within 18 months of the 1088 Closing Date; and
- e) \$600,000 and 1,125,000 common shares within 24 months after the Closing Date. Pending the payment of the Consideration in full, the Company has granted a mortgage over its land in favor of the 1088 Shareholders.
- * On February 24, 2021, the Company and 1088 shareholders agreed to delay the payment by 56 days from the initial payment date at \$318 per day for a total penalty of \$17,797. The amended balance of \$217,797 was paid by the Company on February 24, 2021. The next instalment is not due until September 2021.

The details of the purchase have been accounted for as follows:

| Cash to be paid, discounted | \$ 1,162,045 |
|--|-----------------|
| Fair Value of common shares to be issued | 585,925 |
| Total consideration | \$ 1,747,970 |
| Land acquired | \$ 1,747,970 |

During the period ended November 30, 2020, the Company issued 375,000 shares with a value of \$106,177 pursuant to terms of the 1088 Agreement and had consideration payable of 2,625,000 common shares to 1088 Shareholders valued at \$479,748. The Company discounted the cash consideration using a discount rate of 20% to reflect the time value of money related to future cash outlays and share issuances, resulting in a present value of \$1,747,970 and discounted future share issuances using the average strike put-option model at acquisition date. During the period ended November 30, 2020, the company recognized accretion expense of \$54,193. As at November 30, 2020, the Company has a cash consideration payable to 1088 of \$1,216,238.

During the period ended May 31, 2021, the Company recognized accretion expense of \$96,995. As at May 31, 2021, the Company has a consideration payable to 1088 of \$1,113,233.

During the period ended November 30, 2020, the Company recorded impairment on the land of \$1,450,000 to management's best estimate of its recoverable amount of \$297,970.

Asset Acquisition (Continued)

Lords of Grasstown Holdings Ltd.

On February 22, 2021, the Company closed a share purchase agreement (the "Grasstown Agreement") with Lords of Grasstown Holdings Ltd. ("Grasstown"), a company existing under the laws of the Canada, to acquire all of the issued and outstanding shares of Grasstown. Grasstown owns 100% of the interest its intellectual property.

The Company will pay an aggregate of \$50,000 in cash and issued an aggregate of 6 million common shares to the Grasstown Shareholders, pro rata in accordance with their holdings as follows (the "Grasstown Consideration"):

- a) \$50,000 paid within 30 days from the date of Closing (the "Grasstown Closing Date") (paid); and
- b) \$6,000,000 common shares issued on February 22, 2021.

The details of the purchase have been accounted for as follows:

| Fair Value of the common shares issued Cash to be paid | \$ 1,410,000 50,000 |
|---|---------------------------|
| Total consideration | \$ 1,460,000 |
| Intangible assets acquired | \$ 1,460,000 |

The consideration payable as at May 31, 2021 is \$Nil.

Reverse Takeover Transaction

On April 28, 2020, the RTO was completed whereby MLK acquired 100% of the issued and outstanding common shares of 1157630 and Go Green in exchange for 40,000,000 common shares issued to 1157630. Immediately prior to the completion of the RTO, MLK had 12,249,629 common shares and 6,914,333 share purchase warrants that had their expiry dates extended to April 28, 2021. These warrants had expiry dates between March 29, 2020 to August 16, 2020. Upon completion of the RTO, MLK changed its name to Pac Roots Cannabis Corp. Common shares of 1157630 were exchanged for equivalent securities of the Company on one-for-one the basis.

Prior to the completion of the RTO, MLK paid on behalf of 1157630 certain expenses and made cash advances to fund ongoing operations. Concurrent with the RTO, the Company spun off its interest in mineral properties interest to its subsidiary 1167343 B.C. Ltd. ("Newco") (the "Spin-Off").

Reverse Takeover Transaction (Continued)

The RTO has been accounted for as an asset acquisition on the basis that MLK did not meet the definition of a business as it had no ongoing business operations. As 1157630 is deemed to be the acquirer for accounting purposes, its assets, liabilities and operations since incorporation are included in these condensed interim consolidated financial statements at their historical carrying values. MLK's results of operations have been included from April 28, 2020, the date of the RTO. For purposes of this transaction, the consideration paid was the fair value of the equity of the Company retained by the shareholders of MLK. This amount was calculated as follows:

| Fair value of 12,249,629 notional common shares at \$0.30 per share | \$ 3,674,889 |
|---|-----------------|
| Fair value of 6,914,333 warrants assumed | 730,000 |
| Total consideration | 4,404,889 |
| | |
| Cash | 161,516 |
| Amount receivable | 41,944 |
| Advances to 1157630 | 1,844,909 |
| Exploration and evaluation assets | 211,516 |
| Equipment | 3,470 |
| Accounts payable and accrued liabilities | (589,338) |
| Notes payable | (66,000) |
| Loans | (300,000) |
| Net identifiable assets acquired | 1,308,017 |
| | 2.006.072 |
| | 3,096,872 |
| Transaction cost, 200,000 shares issued to a finder at \$0.30 per share | 60,000 |
| _Listing expense | \$ 3,156,872 |

Plan of arrangement

On May 22, 2020, the Company completed the plan of arrangement ("Arrangement") with its subsidiary 1167343 B.C. Ltd. ("Spinco"). The Company transferred all of its interest in mineral properties, \$550,000 for working capital purposes and certain liabilities (the "Mineral Property Assets"). As consideration for the Mineral Property Assets, all shareholders of the Company as of April 28, 2020 received common shares of the Spinco on a one-for-one basis.

The distribution date for the Spinco shares was May 27, 2020 (the "Distribution Date"). The shares of Spinco will not be listed on any exchange on the Distribution Date.

As the Arrangement occurred between companies under common control and the transfer was reflected at carrying values and was recorded as a capital transaction through equity. The carrying values of the net assets and liabilities transferred and acquired pursuant to the Arrangement consisted of the following:

| Mineral Property Assets transferred: | |
|---|---------------|
| Cash payable to Spinco | \$ 550,000 |
| Exploration and evaluation properties | 211,516 |
| Notes payable | (66,000) |
| Accounts payable related to exploration and evaluation properties | (52,989) |
| Total | \$ 642,527 |

After the completion of the Arrangement, the Company does not have any exploration and evaluation properties recorded as at November 30, 2020 and May 31, 2021.

On September 8, 2020, the Company made the cash payment to Spinco of \$550,000.

Rock Creek Farms Joint Venture

The PacRoots and Rock Creek Farms 100-acre premium hemp joint venture commenced in late May after receiving the hemp cultivation license from Health Canada on May 22nd, 2020. The operations team spent several weeks working the fields, installing irrigation systems, before planting began in mid-June. There are approximately 130,000 premium hemp CBD plants in the ground across two 50-acre parcels. Seedlings were planted systematically in rows in the field after spending the first month in greenhouses, ensuring optimal growth while minimizing environmental influences in the early stage.

On June 30, 2020 and amended on March 10, 2021, the Company entered into an agreement (the "Investment Agreement") with Rock Creek Farms Ltd. ("Rock Creek") for the formation of 1293953 BC Ltd. (the "Rock Creek Farms Joint Venture"), which is 49% owned by Pac Roots and 51% by Rock Creek Farms Ltd. The Company's contribution to the joint venture was an aggregate of \$300,000 in capital. The Company contributed the capital in the prior year. Rock Creek will contribute two commercial leases, consulting services, cultivation equipment, agricultural infrastructure and intellectual property relating to commercial scale hemp operations and proprietary biomass storage techniques (the "Rock Creek Capital Contribution"). Profits generated from the joint venture will be distributed first to the Company until its capital contributions have been repaid and thereafter in accordance with the interests in the joint venture held by the parties. As at May 31, 2021 the Company has \$300,000 recorded in the investment in the Rock Creek Farms Joint Venture.

On March 11, 2021, the Company was issued 300,000 shares of 1293953 BC Ltd. Pursuant to the Investment Agreement signed with Rock Creek Farms Ltd., these shares effectively represent 49% of the Rock Creek Farms Joint Venture owned by the Company.

Pac Roots and Rock Creek Farms deploy traditional and customized hemp farming techniques, while utilizing the rich native soil. We optimize cultivation through these unique methods:

- Our nutrients are custom formulated from raw salts for specific cultivars.
- Systematic planting of cultivars that are stress-tested, planted young and hardy, measuring up to 18 inches, providing maximum opportunity for growth and resilience.
- Row compaction and mowing for weed control, enabling a selected harvest
- Complex irrigation systems with direct nutrient and spring water delivery to each plant site.

Summary of Quarterly Results

| Quarter end | 3 months ending May 31 2021 | 3 months ending February 28 2021 | 3 months ending November 30 2020 | 3 months ending August 31, 2020 |
|------------------------------------|--------------------------------|-------------------------------------|-------------------------------------|------------------------------------|
| | \$ | \$ | \$ | \$ |
| Assets | 3,293,497 | 4,199,578 | 1,861,540 | 4,740,581 |
| Expenses | (289,661) | (999,870) | (262,167) | (827,290) |
| Net and comprehensive loss | | | | |
| | (288,511) | (969,870) | (5,337,543) | (826,911) |
| Loss per share – basic and diluted | (0.00) | (0.01) | (0.08) | (0.01) |

| Quarter end | 3 months ending May 31, 2020 | 3 months ending February 29, 2020 | 3 months ending November 30, 2019 | 3 months ending August 31, 2019 |
|------------------------------------|---------------------------------|--------------------------------------|--------------------------------------|------------------------------------|
| | \$ | \$ | \$ | \$ |
| Assets | 4,926,174 | 962,184 | 1,008,200 | 782,136 |
| Expenses | (180,638) | (83,825) | (115,122) | (283,300) |
| Net and | | | | |
| comprehensive loss | | | | |
| | (2,493,256) | (83,825) | (115,122) | (298,300) |
| Loss per share – basic and diluted | (0.06) | (0.00) | (0.00) | (0.01) |

Summary of Quarterly Results (Continued)

| EXPENSES Accretion and interest Advertising and promotion | ended, May 31, 2021 63,362 29,052 | ended, May 31, 2020 | ended, May 31,2021 | ended May 31,2020 |
|---|--|------------------------|-----------------------|----------------------|
| Accretion and interest | 63,362 | • | May 31,2021 | May 31,202 |
| Accretion and interest | | 8 524 | | |
| | | 8 524 | | |
| Advertising and promotion | 29,052 | 0,524 | \$ 127,226 | \$ 16,72 |
| | | 42,768 | 238,526 | 42,768 |
| Amortization of right-of-use asset | 27,709 | 23,505 | 55,418 | 47,010 |
| Consulting fees | 123,267 | 48,715 | 239,717 | 56,71: |
| Foreign exchange loss (gain) | 1,433 | - | 1,199 | |
| Insurance (recovery) | 5,696 | 1,765 | 6,579 | 11: |
| License fees recovery | - | - | (1,000) | |
| Management fees | - | 10,000 | - | 25,00 |
| Office and miscellaneous | | | | |
| expense (recovery) | 8,028 | 44,988 | (5,573) | 46,79 |
| Professional fees | 10,015 | 7,747 | 18,015 | 22,11 |
| Rent | 715 | (13,561) | 5,221 | (3,220 |
| Repairs and maintenance | 344 | 543 | 1,033 | 2,34 |
| Regulatory and filing fees | 14,473 | - | 22,153 | |
| Share-based payments | - | - | 574,601 | |
| Travel | - | 4,225 | - | 4,22 |
| Utilities | 5,567 | 1,419 | 6,416 | 3,87 |
| Total Expenses | (289,661) | (180,638) | (1,289,531) | (264,463 |
| Other Income (Expenses) | | | | |
| Gain on settlement of debt | 1,150 | - | 1,150 | |
| Gain on write-off of accounts | | | | |
| payable | - | - | 30,000 | |
| Interest earned | - | 777 | - | 77 |
| Listing expense | - | (2,185,748) | - | (2,185,748 |
| Transaction cost | - | (60,000) | - | (60,000 |
| Write-off of accounts receivable | - | (67,647) | - | (67,647 |
| Total Other Income (Expenses) | 1,150 | (2,312,618) | 31,150 | (2,312,618 |
| Loss and comprehensive loss for the period | \$ (288,511) | \$ (2,493,256) | \$ (1,258,381) | \$ (2,577,081 |

During the period ended May 31, 2021, the Company completed the Grasstown acquisition, a private placement and had minimal operating expenditures.

Results of Operations

The Company's loss for the six months ended May 31, 2021 was \$1,258,381 compared to a loss of \$2,577,081 for the six months ended May 31, 2020. In general, the Company had less activity during the six months ended May 31, 2021. In the comparative period in the prior year, the Company incurred higher expenditures as a result of the acquisitions and transactions completed during the prior year.

- Accretion and interest increased to \$127,226 from \$16,721 due to the Company's adoption of IFRS 16 Leases, the Company recorded interest expenses regarding its lease liabilities resulting from its right-of-use assets relating to its commercial lease and recorded accretion related to consideration payable for the asset acquisitions in the prior year.
- Advertising and promotion increased to \$238,526 from \$42,768. The increase is due to investor relations costs to assist the Company raise equity capital.
- Amortization of right-of-use asset increased to \$55,418 from \$47,010 due to the Company's adoption of IFRS 16 Leases, the Company recognized and amortized its right-of-use asset related to its commercial leases. The Company entered into a second lease agreement in the third quarter of the prior year, resulting in a higher expense for the period ended May 31, 2021.
- Consulting fees increased to \$239,717 from \$56,715 as the Company expanded as a result of the various transactions in the prior year. The Company relies heavily on consultants to achieve its goals on all facets of business and these industry consultants bring a wide range of expertise and connections to the Company. Consultants include the Management and Directors of the Company, and other support roles.
- License fees decreased to \$(1,000) from \$Nil as a result of recoveries during the period.
- Management fees decreased to \$Nil from \$25,000 as a result of the change of management that occurred as a result of the RTO during the period ended November 30, 2020 and the change in recording compensation from management fees to consulting fees.
- Insurance expense increased to \$6,579 from \$113 as a result of the Company incurring insurance costs for the Kelowna facility.
- Office and miscellaneous expenses decreased to \$(5,573) from \$46,794 as a result of the Company recovery certain costs during the current period.
- Professional fees decreased to \$18,015 from \$22,110. In the prior year, the Company incurred legal, accounting, and other professional fees related to the completion of acquisitions and the RTO.
- Rent increased to \$5,221 from \$(3,220) as a result of the Company's adoption of IFRS 16 Leases, where the Company recorded a right-of-use asset and amortizes this asset on a periodic basis rather than recording rent expenditures. During the period ended May 31, 2021, the rent expenditures relate to the property taxes portion of the lease.
- Repairs and maintenance decreased to \$1,033 from \$2,349 as a result of the Company having assets that are not yet available for use during the current period.
- Regulatory and filing fees increased to \$22,153 from \$Nil as a result of the completion of the RTO in the prior year, requiring filings for the Company during the current period.
- Share-based payments increased to \$574,601 as a result of the Company's granting of stock options to directors, officers and consultants of the Company.
- Utilities increased to \$6,416 from \$3,878 as a result of the expansion of the Company in the prior year.
- Gain on write-off of accounts payable increased to \$30,000 from \$Nil as a result of the Company cancelling an agreement with a vendor.

Results of Operations (Continued)

- Gain on settlement of debt increased to \$1,150 as a result of the Company settling debt with a certain vendor.
- Interest earned decreased to \$Nil from \$777 as a result of the Company not earning interest in the current period.
- Listing expense decreased to \$Nil from \$2,185,748. In the comparative period in the prior year, the Company completed a RTO and incurred listing costs related to acquisitions.
- Transaction costs decreased to \$Nil from \$60,000. In the comparative period in the prior year, the Company completed a RTO and incurred transaction costs.
- Write-off of accounts receivable decreased to \$Nil from \$67,647. In the comparative period in the prior year, the Company wrote off certain receivables it deemed were uncollectible.

Liquidity and Capital Resources

As at May 31, 2021, the Company has a working capital deficiency of \$930,565 compared to a working capital deficiency of \$1,136,344 at November 30, 2020 as a result of the completion of the private placement during the period.

Operating Activities

For the period ended May 31, 2021, the Company used cash of \$779,901 from operating activities (period ended May 31, 2020 - \$607,574), for normal operating expenses. The Company also incurred non-cash expenditures of \$574,601 relating to share-based payments in the current period and recorded accretion of \$132,932.

Investing Activities

During the period ended May 31, 2021, the Company used cash of \$267,797 (May 31, 2020 - \$47,425) in investing activities which consisted of the cash consideration paid to 1088 from the prior year agreement and Lords of Grasstown for the acquisition in the current year. In the prior period, the Company purchased property and equipment of \$47,081 and used cash of \$164 for the RTO.

Financing Activities

Finally, the Company received cash of \$1,150,715 (May 31, 2020 - \$1,386,094) from financing activities. The Company completed a private placement, received loans, made lease payments and loan repayments during the current period. In the prior period, the Company completed a private placement and made lease payments.

The Company's principal assets are at a start-up stage and as a result the Company has no current source of operating cash flows. The Company relies on its ability obtain equity financing to fund administration expenses and future operations. The ability of the Company to continue as a going concern and to realize the carrying value of its assets and discharge its liabilities when due is dependent on the successful completion of a financing or by monetizing assets. There is no certainty that these and other strategies will be successful.

Share Capital and Events Subsequent to May 31, 2021

The Company's authorized capital consists of an unlimited number of common shares without nominal or par value. As of the date of this MD&A, the Company has 87,027,899 issued and outstanding common shares, 22,469,317 share purchase warrants and 7,500,000 stock options.

Related Party Transactions and Balances

The Directors and Executive Officers of the Company as of the date of this report are as follows:

Patrick Elliott Director, President and CEO

James Henning Chief Financial Officer and Corporate Secretary
William Fleming Former Director, Corporate Secretary and CFO

Alex Field Former President and Director, Current Director of Go Green

Paul K. Smith Former President, CEO and Interim CFO

Chad Clelland Director
Marc Geen Former Director
Matthew McGill Director

Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Related parties may be individuals or corporate entities. A transaction is considered to be a related party transaction when there is a transfer of resources or obligations between related parties. The following table lists the compensation costs paid directly or to companies controlled by key management personnel for the period ended May 31, 2021:

| Six months ended May 31, 2021 | | | | |
|---|--------------------------------------|-----------------------------|--|--|
| · | Consulting and Management Fees | Share-based Compensation | | |
| Consulting fees paid/accrued to the CEO | - | 87,817 | | |
| Consulting fees paid/accrued to a company controlled by the | | | | |
| CEO | 45,000 | - | | |
| Consulting fees paid/accrued to a company controlled by the | | | | |
| CFO | 3,000 | - | | |
| Share-based payments to the CFO | · - | 14,636 | | |
| Share-based payments to directors of the Company | - | 65,863 | | |
| Share-based payments to a former director of the Company | | | | |
| | - | 29,272 | | |
| | \$ 48,000 | \$ 197,588 | | |

| Six months ended May 31, 2020 | | | | |
|--|--------------------------------------|-----------------------------|--|--|
| | Consulting and Management Fees | Share-based Compensation | | |
| Management fees paid/accrued to the former President and | 40,000 | - | | |
| director | | | | |
| Directors fees accrued to directors | 24,000 | - | | |
| Directors fee accrued to a former CEO/CFO | 12,000 | - | | |
| Consulting fees accrued to the CEO | 21,000 | - | | |
| | \$ 97,000 | \$ - | | |

Included in accounts payable and accrued liabilities at May 31, 2021 is \$357,318 (November 30, 2020 - \$442,965) owing to current and former directors, companies controlled by directors or companies with directors in common.

Commitments

The Company has entered into an agreement to lease its warehouse and production facility in Kelowna, British Columbia commencing during 2018 and expiring on March 31, 2022 and a lease for office space in Vancouver, British Columbia commencing on October 1, 2020 and expiring on September 30, 2021. The Company also has obligations to make cash and share payments related to its asset acquisitions during the period ended May 31, 2021.

Off-Balance Sheet Arrangements

The Company has no off-balance sheet arrangements.

Critical accounting estimates

Recoverability of asset carrying values

When there are indications that an asset may be impaired, the Company is required to estimate the asset's recoverable amount. Recoverable amount is the greater of value in use and fair value less costs to sell. Determining the value in use requires the Company to estimate expected future cash flows associated with the assets and a suitable discount rate in order to calculate present value.

Estimated useful lives and impairment considerations

Depreciation and amortization of property, equipment and intangible assets are dependent upon estimates of useful lives, which are determined through the exercise of judgment. The assessment of any impairment of these assets is dependent upon estimates of recoverable amounts that take into account factors such as economic and market conditions and the useful lives of assets.

Business combination vs asset acquisition

Judgment is used in determining whether an acquisition is a business combination or an asset acquisition. More specifically, management concluded that the Company's acquisitions did not represent a business, as the assets acquired were not an integrated set of activities with inputs, processes and outputs. For acquisitions that represented the purchase of assets, no goodwill was recognized on the transactions and acquisition costs were capitalized to the assets purchased rather than expensed. As the Company concluded that the acquisitions during the year were asset acquisitions, an allocation of the purchase price to the individual identifiable assets acquired and liabilities assumed based on their fair values at the date of purchase was required. The fair values of the net assets acquired were calculated using significant estimates and judgments. If estimates or judgments differed, this could result in a materially different allocation of net assets on the condensed interim consolidated statement of financial position.

Share-based payments

The amounts recorded for share-based payments are based on estimates. The Black Scholes model used to determine the fair value of stock options and finder warrants is based on estimates of assumptions for expected volatility, expected number of options to vest, dividend yield, risk-free interest rate, expected forfeitures and expected life of the options. The average strike put-option model used to discount future share issuances is based on estimates of assumptions for expected volatility and dividend yield. Changes in these assumptions may result in a material change to the amounts recorded for the issuance of stock options and finders warrants, and the discounted amount of future share issuances.

Deferred tax assets

The estimation of income taxes includes evaluating the recoverability of deferred tax assets based on an assessment of the Company's ability to utilize the underlying future tax deductions against future taxable income prior to expiry of those deductions. Management assesses whether it is probably that some or all of the deferred income tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income. To the extent that management's assessment of the Company's ability to utilize future tax deductions changes, the Company would be required to recognize more or fewer deferred tax assets, and deferred income tax provisions or recoveries could be affected.

Critical accounting estimates (Continued)

Discount rate used for consideration payable

The carrying value of the consideration payable is subject to management's estimates in determining an appropriate discount rate based on similar liabilities, the Company's borrowing rate, and other factors.

Going concern

The assessment of the Company's ability to execute its strategy by funding future working capital requirements involves judgement. Management monitors future cash requirements to assess the Company's ability to meet these future funding requirements. Further information regarding going concern is outlined in Note 1 of the condensed interim consolidated financial statements.

Financial Instruments

The Company's financial instruments are categorized in a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 - inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices).

Level 3 - inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The Company's financial instruments include cash, accounts payable and accrued liabilities, amounts payable to MLK, lease liabilities, consideration payable, and loan payable.

The fair value of cash and restricted cash are determined based on "Level 1" inputs, which consist of quoted prices in active markets for identical assets. The fair value of advances is determined to be "Level 3" as the amount relates to advances made concerning a definitive share purchase agreement; therefore, the inputs are unobservable.

Assets measured at fair value on a recurring basis were presented on the Company's statement of financial position as at November 30, 2020 and May 31, 2021 are as follows:

| | Fair Value Measur | rements Using | | |
|-------------------|-------------------|---------------|--------------|------------|
| | Quoted Prices | | | |
| | in Active | Significant | Significant | |
| | Markets for | Other | Other | |
| | Identical | Observable | Unobservable | |
| | Instruments | Inputs | Inputs | |
| | (Level 1) | (Level 2) | (Level 3) | Total |
| | \$ | \$ | \$ | \$ |
| November 30, 2020 | | | | |
| Assets | | | | |
| Cash | \$ 27,775 | \$ - | \$ - | \$ 27,775 |
| May 31, 2021 | | | | |
| Assets | | | | |
| Cash | \$ 130,792 | \$ - | \$ - | \$ 130,792 |

Financial Instruments (Continued)

Credit risk

Credit risk is the risk of potential loss to the Company if a counter party to a financial instrument fails to meet its payment obligations. The Company is exposed to credit risk with respect to its cash.

The Company's credit risk is primarily attributable to cash. Management believes that the credit risk concentration with respect to cash is remote as it maintains accounts with highly-rated financial institutions.

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its obligations as they become due. The Company manages its liquidity risk by forecasting cash flows from operations and anticipated investing and financing activities. As at May 31, 2021, the Company had current liabilities of \$1,317,256 (November 30, 2020 - \$1,495,659). Based on the current funds held, the Company does not have sufficient working capital for the short term, and thus will need to rely upon financing from shareholders and/or debt holders to obtain sufficient working capital. There is no assurance that such financing will be available on terms and conditions acceptable to the Company.

The following is a table of the Company's maturity of its liabilities as at May 31, 2021, excluding accounts payable and accrued liabilities.

| | 250,000 | 1,300,000 | 86,746 | 7,580 | 1,644,326 |
|------------------------|-----------|-----------|-------------------------------|-----------|-----------|
| Due in 3 or more years | - | - | - | - | - |
| Due in 2 years | 200,000 | 1,000,000 | 28,915 | - | 1,228,915 |
| Due in 1 year | 50,000 | 300,000 | 57,831 | 7,580 | 415,411 |
| | \$ | \$ | \$ | \$ | \$ |
| | | | | Lease | Total |
| | Agreement | Agreement | | Vancouver | |
| | Phenome | 1088 | Go Green Lake County Lease | | |

Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate due to changes in market prices. Market risk comprises three types of risk: interest rate risk, foreign currency risk and other price risk.

(i) Interest rate risk

Interest rate risk consists of two components:

To the extent that payments made or received on the Company's monetary assets and liabilities are affected by changes in the prevailing market interest rates, the Company is exposed to interest rate cash flow risk.

To the extent that changes in prevailing market rates differ from the interest rate in the Company's monetary assets and liabilities, the Company is exposed to interest rate price risk.

The Company is not exposed to significant interest rate risk.

Financial Instruments (Continued)

Market risk (Continued)

(ii) Foreign currency risk

The Company is not exposed to foreign currency risk.

(iii) Other price risk

Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices, other than those arising from interest rate risk or foreign currency risk. The Company does not hold any equity securities and therefore does not have significant exposure to price risk.

Accounting standards adopted in the current period

IFRS 16 Leases

On September 1, 2019, the Company adopted IFRS 16, which specifies how an entity will recognize, measure, present and disclose leases. The standard provides a single lessee accounting model, requiring lessees to recognize assets and liabilities for all leases unless the lease term is twelve months or less or the underlying asset has a low value. Lessors continue to classify leases as operating or finance, with IFRS 16's approach to lessor accounting substantially unchanged from its predecessor, International Accounting Standard ("IAS") 17 Leases. The standard was issued in January 2016 and is effective for annual periods beginning on or after January 1, 2019.

The Company has elected to apply IFRS 16 using a modified retrospective approach, which does not require restatement of prior period financial information. On the date of transition, the Company recorded a right-of-use asset and lease liability of \$242,890, discounted using the Company's incremental borrowing rate of 15%.

Risks and Uncertainties

Under Canadian reporting requirements, management of the Company is required to identify and comment on significant risks and uncertainties associated with its business activities.

Warrants are Speculative in Nature and may not have any Value

The Warrants do not confer any rights of Common Share ownership on their holders, such as voting rights or the right to receive dividends, but rather merely represent the right to acquire Common Shares at a fixed price for a limited period of time. Moreover, the market value of the Warrants, if any, is uncertain and there can be no assurance that the market value of the Warrants will equal or exceed their imputed offering price. There can be no assurance that the market price of the Common Shares will ever equal or exceed the exercise price of the Warrants, and consequently, whether it will ever be profitable for holders of the Warrants to exercise their Warrants.

Volatility of Stock Price and Market Conditions

The market price of the common shares may be subject to wide fluctuations in response to factors such as actual or anticipated variations in its results of operations, changes in financial estimates by securities analysts, general market conditions and other factors. Market fluctuations, as well as general economic, political and market conditions such as recessions, interest rate changes or international currency fluctuations, may adversely affect the market price of the common shares, even if the Company is successful in maintaining revenues, cash flows or earnings. The purchase of the common shares involves a high degree of risk and should be undertaken only by investors whose financial resources are sufficient to enable them to assume such risks and who have no need for immediate liquidity in their investment. Securities of the Company should not be purchased by persons who cannot afford the possibility of the loss of their entire investment. Furthermore, an investment in the Company should not constitute a major portion of an investor's portfolio.

Risks and Uncertainties (Continued)

Negative Cash Flow from Operations

During the six months ended May 31, 2021, the Company sustained net losses from operations. Although the Company anticipates it will have positive cash flow from operating activities in future periods, it is possible the Company may have negative cash flow in any future period as the Company continues to progress its expansion plans and its capacity of operations.

Environmental Regulations and Risks

The Company's operations are subject to environmental regulation in the various jurisdictions in which it operates. These regulations mandate, among other things, the maintenance of air and water quality standards and land reclamation. They also set forth limitations on the generation, transportation, storage and disposal of solid and hazardous waste. Environmental legislation is evolving in a manner which will require stricter standards and enforcement, increased fines and penalties for non-compliance, more stringent environmental assessments of proposed projects and a heightened degree of responsibility for companies and their officers, directors and employees. There is no assurance that future changes in environmental regulation, if any, will not adversely affect the Company's operations.

Government approvals and permits are currently, and may in the future be required in connection with the Company's operations. To the extent such approvals are required and not obtained, the Company may be curtailed or prohibited from its proposed production of cannabis or from proceeding with the development of its operations as currently proposed.

Failure to comply with applicable laws, regulations and permitting requirements may result in enforcement actions thereunder, including orders issued by regulatory or judicial authorities causing operations to cease or be curtailed, and may include corrective measures requiring capital expenditures, installation of additional equipment, or remedial actions. The Company may be required to compensate those suffering loss or damage by reason of its operations and may have civil or criminal fines or penalties imposed for violations of applicable laws or regulations.

Amendments to current laws, regulations and permits governing the production of cannabis, or more stringent implementation thereof, could have a material adverse impact on the company and cause increases in expenses, capital expenditures or production costs or reduction in levels of production or require abandonment or delays in development.

Early Stage of Development

The Company, while incorporated in 2012, began carrying on business in 2021 and has yet to generate revenue from the sale of products to date. The Company is therefore subject to many of the risks common to early-stage enterprises, including under-capitalization, cash shortages, limitations with respect to personnel, financial, and other resources and lack of revenues. There is no assurance that the Company will be successful in achieving a return on shareholders' investment and the likelihood of success must be considered in light of the early stage of operations.

Lack of Growing Facility and Construction Risk Factors

The Company's activities and resources have been primarily focused on the facility in Kelowna, British Columbia (the "Facility"). The Company has yet to complete the construction of this Facility. Adverse changes or developments affecting the construction of this Facility could have a material and adverse effect on the Company's ability to produce cannabis, its business, financial condition and prospects.

Cultivation Risks

The Company's business involves the growing of cannabis, an agricultural product. Such business will be subject to the risks inherent in the agricultural business, such as insects, plant diseases and similar agricultural risks. Although the Company expects that any such growing will be completed indoors under climate-controlled conditions, there can be no assurance that natural elements will not have a material adverse effect on any such future production.

Risks and Uncertainties (Continued)

Changes in Laws, Regulations and Guidelines

On December 20, 2017, the Prime Minister communicated that the Canadian Federal Government intends to legalize cannabis in the summer of 2018, despite previous reports of a July 1, 2018 deadline. On June 7, 2018, Bill C45 passed the third reading in the Senate with a number of amendments to the language of the Cannabis Act. On June 20, 2018, Prime Minister Trudeau announced that cannabis would be legal by October 17, 2018. On June 21, 2018, the Government of Canada announced that Bill C-45 received Royal Assent. Bill-C-45 will come into force on October 17, 2018. On July 11, 2018, the regulations made pursuant 27 to the Cannabis Act were published. The regulations under the Cannabis Act contemplate the various licences including cultivation, processing, analytical testing, sale (including medical sales), analytical testing and scientific research. The regulations introduced the nursery and made outdoor cultivation permissible. Finally, the requirements for packaging and labelling of products for both medical and non-medical consumption were explicitly set forth. The impact of changes in the regulatory enforcement by Health Canada under the Cannabis Act and its regulations, particularly in respect of product packaging, labelling, marketing, advertising and promotions and product approvals and its impact on the Company's business are unknown at this time.

In addition, when the Cannabis Act comes into effect, there is no guarantee that provincial legislation regulating the distribution and sale of cannabis for adult use purposes will be enacted according to the terms announced by such provinces, or at all, or that any such legislation, if enacted, will create the opportunities for growth anticipated by the Company. For example, the Provinces of Québec and New Brunswick have announced sales and distribution models that would create government-controlled monopolies over the legal retail and distribution of cannabis.

Legislative or Regulatory Reform and Compliance

The commercial cannabis industry is a new industry and the Company anticipates that such regulations will be subject to change as the Federal Government monitors Licensed Producers operations. The Company's operations are subject to a variety of laws, regulations, guidelines and policies relating to the manufacture, import, export, management, packaging/labelling, advertising, sale, transportation, storage and disposal of cannabis but also including laws and regulations relating to drugs, controlled substances, health and safety, the conduct of operations and the protection of the environment. While to the knowledge of management, the Company is currently in compliance with all such laws, any changes to such laws, regulations, guidelines and policies due to matters beyond the control of the Company may cause adverse effects to its operations.

Negative Customer Perception

The Company believes the cannabis industry is highly dependent upon consumer perception regarding the medical benefits, safety, efficacy and quality of the cannabis distributed for medical purposes to such consumers. Consumer perception of the Company's products can be significantly influenced by scientific research or findings, regulatory investigations, litigation, political statements both in Canada and in other countries, media attention and other publicity (whether or not accurate or with merit) regarding the consumption of cannabis products for medical or recreational purposes, including unexpected safety or efficacy concerns arising with respect to the products of the Company or its competitors. There can be no assurance that future scientific research, findings, regulatory proceedings, litigation, media attention or other research findings or publicity will be favorable to the medical cannabis market or any particular product, or consistent with earlier publicity. Future research reports, findings, regulatory proceedings, litigation, media attention or other publicity that are perceived as less favorable than, or that question, earlier research reports, findings or publicity could have a material adverse effect on the demand for the Company's products and the business, results of operations and financial condition of the Company. The Company's dependence upon consumer perceptions means that adverse scientific research reports, findings, regulatory proceedings, litigation, media attention or other publicity (whether or not accurate or with merit), could have an adverse effect on any demand for the Company's products which could have a material adverse effect on the Company's business, financial condition and results of operations.

Further, adverse publicity reports or other media attention regarding the safety, efficacy and quality of cannabis for medical purposes in general, or the Company's products specifically, or associating the consumption of cannabis with illness or other negative effects or events, could have such a material adverse effect. Such adverse publicity reports or other media attention could arise even if the adverse effects associated with such products resulted from consumers' failure to consume such products legally, appropriately or as directed.

Risks and Uncertainties (Continued)

Constraints on Marketing Products

In view of the restrictions on marketing, advertising and promotional activities set forth in the Cannabis Act and related regulations, the Company's business and operating results may be hindered by applicable restrictions on sales and marketing activities imposed by Health Canada. If the Company is unable to effectively market its products and compete for market share, or if the costs of compliance with government legislation and regulation cannot be absorbed through increased selling prices for its products, the Company's sales and operating results could be adversely affected.

Reliance on Receiving a Research and Development License and subsequent Cultivation and Processors License
The Company's ability to set up its Facility for the purposes of research and development and to grow, store and sell cannabis in Canada is dependent on Health Canada's approval of the Company's RDL and subsequent cultivation and processor licenses (the "Licenses"). The Licenses are subject to ongoing compliance and reporting requirements. Failure to comply with the requirements of the Licenses or any failure to maintain the Licenses would have a material adverse impact on the business, financial condition and operating results of the Company. The Company is in the process of applying for the cultivation and processor license for cannabis in Canada. Although the Company believes it will meet the requirements for future extensions or renewals of the Licenses, there can be no guarantee that Health Canada will extend or renew these Licenses or, if extended or renewed, that they will be extended or renewed on the same or similar terms.

In Canada, few applicants for a license from Health Canada ultimately receive a license to produce and sell cannabis. Major expenditures may be required in pursuit of a license and it is impossible to ensure that the expenditures will result in receipt of a license and a profitable operation. There can be no assurances that the Company will maintain a license to produce and sell cannabis and be brought into a state of commercial production. Should a license not be extended or renewed or should it be issued or renewed on terms that are less favourable to the Company than anticipated, the business, financial condition and results of the operations of the Company could be materially adversely affected.

New Product Development

The Company's ability to sell cannabis in Canada is dependent on the Company's ability to develop product that exceeds the standards set by Health Canada. Although the Company believes management has the expertise to develop such products, there is no assurance that the Company will successfully develop new products.

Competition

There is potential that the Company will face intense competition from other companies, some of which can be expected to have longer operating histories and more financial resources and experience than the Company. Currently, the cannabis industry generally is comprised of individuals and small to medium-sized entities, however, the risk remains that large conglomerates and companies who also recognize the potential for financial success through investment in this industry could strategically purchase or assume control of certain aspects of the industry. In doing so, these larger competitors could establish price setting and cost controls which would effectively "price out" many of the individuals and small to medium-sized entities who currently make up the bulk of the participants in the varied businesses operating within and in support of the medical and adult-use cannabis industry. While most laws and regulations seemingly deters this type of takeover, this industry remains quite nascent, so what the landscape will be in the future remains largely unknown, which in itself is a risk. Because of the early stage of the industry in which the Company will operate, the Company expects to face additional competition from new entrants. To become and remain competitive, the Company will require research and development, marketing, sales and support.

Additional Financing

The Company may require equity and/or debt financing to undertake capital expenditures or to undertake acquisitions or other business combination transactions. There can be no assurance that additional financing will be available to the Company when needed or on terms that are commercially viable. The Company's inability to raise financing to fund capital expenditures or acquisitions could limit its growth and may have a material adverse effect upon future profitability.

Risks and Uncertainties (Continued)

If additional funds are raised through further issuances of equity or convertible debt securities, existing shareholders could suffer significant dilution. Any debt financing secured in the future could involve restrictive covenants relating to capital raising activities and other financial and operational matters, which may make it more difficult for the Company to obtain additional capital and to pursue business opportunities, including potential acquisitions.

Market Development

Due to the early stage of the legal cannabis industry, forecasts regarding the size of the industry and the sales of products are inherently subject to significant unreliability. A failure in the demand for products to materialize as a result of competition, technological change or other factors could have a material adverse effect on the business, results of operations and financial condition of the Company.

Reliance on Management

The success of the Company is dependent upon the ability, expertise, judgment, discretion and good faith of its senior management and employees. While employment agreements or management agreements are customarily used as a primary method of retaining the services of key employees, these agreements cannot assure the continued services of such employees. Any loss of the services of such individuals could have a material adverse effect on the Company's business, operating results or financial condition.

Operation Permits and Authorizations

The Company may not be able to obtain or maintain the necessary licenses, permits, authorizations or accreditations, or may only be able to do so at great cost, to operate the businesses. In addition, the Company may not be able to comply fully with the wide variety of laws and regulations applicable to the cannabis industry. Failure to comply with or to obtain the necessary licenses, permits, authorizations or accreditations could result in restrictions on a Licensee's ability to operate in the cannabis industry, which could have a material adverse effect on the Company's business.

Liability, Enforcement Complaints, etc.

The Company's participation in the cannabis industry may lead to litigation, formal or informal complaints, enforcement actions, and inquiries by various federal, provincial, or local governmental authorities against it. Litigation, complaints, and enforcement actions involving the business could consume considerable amounts of financial and other corporate resources, which could have an adverse effect on the Company's future cash flows, earnings, results of operations and financial condition.

Product Liability

Certain of the Company's proposed manufacture, process and/or distribute of cannabis products are designed to be ingested by humans, and therefore face an inherent risk of exposure to product liability claims, regulatory action and litigation if products are alleged to have caused significant loss or injury. In addition, previously unknown adverse reactions resulting from human consumption of cannabis alone or in combination with other medications or substances could occur. A product liability claim or regulatory action against the Company could result in increased costs, could adversely affect the Company's reputation, and could have a material adverse effect on the results of operations and financial condition of the Company.

Reliance on Key Inputs

The cultivation, extraction and processing of cannabis and derivative products is dependent on a number of key inputs and their related costs including raw materials, electricity, water and other local utilities. Any significant interruption or negative change in the availability or economics of the supply chain for key inputs could materially impact the business, financial condition and operating results of the Company. Some of these inputs may only be available from a single supplier or a limited group of suppliers.

If a sole source supplier was to go out of business, the Company might be unable to find a replacement for such source in a timely manner or at all. Any inability to secure required supplies and services or to do so on appropriate terms could have a materially adverse impact on the business, financial condition and operating results of the Company.

Risks and Uncertainties (Continued)

Management of Growth

The Company may experience a period of significant growth in the number of personnel that will place a strain upon its management systems and resources. Its future will depend in part on the ability of its officers and other key employees to implement and improve financial and management controls, reporting systems and procedures on a timely basis and to expand, train, motivate and manage the workforce. The Company's current and planned personnel, systems, procedures and controls may be inadequate to support its future operations.

Dividends

The Company does not anticipate paying any dividends in the foreseeable future. Dividends paid by the Company would be subject to tax and, potentially, withholdings.

Intellectual Property

The success of the Company will depend, in part, on the ability to maintain and enhance trade secret protection over the various existing and potential proprietary techniques and processes of the Company. The Company may be vulnerable to competitors who develop competing technology, whether independently or as a result of acquiring access to the proprietary products and trade secrets of the Company. In addition, effective future patent, copyright and trade secret protection may be unavailable or limited in certain foreign countries and may be unenforceable under the laws of certain jurisdictions.

Insurance Coverage

The Company will require insurance coverage for a number of risks. Although Management believes that the events and amounts of liability covered by such insurance policies should be reasonable, taking into account the risks relevant to the Company's business, and the fact that agreements with users contain limitations of liability, there can be no assurance that such coverage will be available or sufficient to cover claims to which the Company may become subject. If insurance coverage is unavailable or insufficient to cover any such claims, the Company's financial resources, results of operations and prospects, could be adversely affected.

Costs of Maintaining a Public Listing

As a public company, there are costs associated with legal, accounting and other expenses related to regulatory compliance. Securities legislation and the rules and policies of the CSE, OTCQB and Frankfurt Stock Exchange require listed companies to, among other things, adopt corporate governance and related practices, and to continuously prepare and disclose material information, all of which add to a company's legal and financial compliance costs. The Company may also elect to devote greater resources than it otherwise would have on communication and other activities typically considered important by publicly traded companies.

Operational Risks

The Company may be affected by a number of operational risks and may not be adequately insured for certain risks, such as, labour disputes; catastrophic accidents; fires; blockades or other acts of social activism; changes in the regulatory environment; impact of non-compliance with laws and regulations; natural phenomena, such as inclement weather conditions, floods, earthquakes and ground movements. There is no assurance that the foregoing risks and hazards will not result in damage to, or destruction of, the Company's Property and Facility, personal injury or death, environmental damage, adverse impacts on the Company's operations, costs, monetary losses, potential legal liability and adverse governmental action, any of which could have an adverse impact on the Company's future cash flows, earnings and financial condition on the Company. Also, the Company may be subject to or affected by liability or sustain loss for certain risks and hazards against which they may elect not to insure because of the cost. This lack of insurance coverage could have an adverse impact on the Company's future cash flows, earnings, results of operations and financial condition.

Difficulty Implementing Business Strategy

The growth and expansion of the Company is heavily dependent upon the successful implementation of its business strategy. There can be no assurance that the Company will be successful in the implementation of its business strategy.

Risks and Uncertainties (Continued)

Available Talent Pool

As the Company grows, it will need to hire additional human resources to continue to develop the business. However, experienced talent in the areas of cannabis research and development, cultivation of cannabis and extraction is difficult to source, and there can be no assurance that the appropriate individuals will be available or affordable to the Company. Without adequate personnel and expertise, the growth of the Company's business may suffer.

Conflicts of Interest

Certain of the Company's directors and officers are, and may continue to be, involved in other business ventures through their direct and indirect participation in corporations, partnerships, joint ventures, etc. that may become potential competitors of the technologies, products and services the Company intends to provide. Situations may arise in connection with potential acquisitions or opportunities where the other interests of these directors and officers' conflict with or diverge from the Company's interests. In accordance with applicable corporate law, directors who have a material interest in or who is a party to a material contract or a proposed material contract with the Company are required, subject to certain exceptions, to disclose that interest and generally abstain from voting on any resolution to approve the contract. In addition, the directors and officers are required to act honestly and in good faith with a view to the Company's best interests.

However, in conflict-of-interest situations, the Company's directors and officers may owe the same duty to another company and will need to balance their competing interests with their duties to the Company. Circumstances (including with respect to future corporate opportunities) may arise that may be resolved in a manner that is unfavourable to the Company.

Ability to Maintain Bank Accounts

While the Company does not anticipate any banking restrictions at this time, there is a risk that banking institutions may not accept payments related to the cannabis industry. Such risks could increase costs for the Company. In the event financial service providers do not accept accounts or transactions related to the cannabis industry, it is possible that the Company may be required to seek alternative payment solutions. If the industry was to move towards alternative payment solutions the Company would have to adopt policies and protocols to manage these changes. The Company's inability to manage such risks may adversely affect the Company's operations and financial performance.

Additional Information

The financial statements and additional information regarding the Company are available on SEDAR at www.sedar.com.